A randomized controlled study evaluating the efficacy and safety of PHPV fusion factor vaginal bacteriostasis gel in the treatment of persistent cervical high-risk human papillomavirus infection

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063608

Enrollment

Unknown

Registered

2022-09-13

Start date

2022-09-14

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical high-risk human papillomavirus infection

Interventions

1:PHPV

2:Interferon

3:observation

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: ? Female patients aged 25-45 with a history of sexual life; ? Patients with HPV typing and HPV E6/E7 mRNA positive test results within one month; ? Subjects were informed and signed the informed consent.

Exclusion criteria

Exclusion criteria: ? During pregnancy or lactation; ? History of hysterectomy and cervical surgery; ? Allergic to the study drug; ? Acute genital tract infection; ? With cervical cancer or high-grade cervical lesions; ? Those who have taken antibiotics in the past 3 months; ? Those with severe liver and kidney dysfunction, diabetes, heart disease, mental disorders and other diseases; ? Those with immune metabolism disorder and abnormal blood coagulation function; ? Unable to cooperate with the research; ? Not suitable to participate in this study with consideration of researcher.

Design outcomes

Primary

Measure	Time frame
HPV typing and quantification;	—

Countries

China

Contacts

Public ContactChun Fu

The Second Xiangya Hospital of Central South University

fuchun0814@csu.edu.cn18627315906

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026